Lyell Immunopharma, Inc.
LYEL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LYEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LYEL
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company developing cell therapies for cancer, with a lead dual-targeting CAR T-cell candidate in Phase 3 trials and a cash position of $74.6M as of 2026-06-30.
Key risk: No approved products or revenue
BioSniper Score
Based on 6 of 6 signals
Market Cap
$356.1M
Cash Runway
17.8 moLead Asset
impt-314 (Phase 2)
Next Catalyst
Phase3_Topline · Jan 1, 2032Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 4 clinical trials · 1 catalyst for Lyell Immunopharma, Inc..
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company developing cell therapies for cancer, with a lead dual-targeting CAR T-cell candidate in Phase 3 trials and a cash position of $74.6M as of 2026-06-30.
- Lyell Immunopharma is focused on developing cell therapies for cancer, with its lead product candidate, rondecabtagene autoleucel, a dual-targeting CAR T-cell therapy, in a Phase 3 randomized controlled trial [sec].
- The company reported cash and equivalents of $74.6M as of 2026-06-30, with no revenue and a net loss of $44.8M for the quarter [sec].
- Lyell raised approximately $100M through stock issuances in 2025 and early 2026, including $50M in March 2026 [sec_mda · as of 2026-08-06].
- The company expects to incur additional losses as it expands R&D and clinical trials, and believes existing cash will fund operations for at least the next 12 months as of 2026-05-06 [sec_mda · as of 2026-05-06].
- Lyell faces typical biotech risks including clinical trial results, regulatory delays, and the need for future capital to support development and commercialization [sec_mda · as of 2026-08-06].
What works
- Lead candidate rondecabtagene autoleucel is in a Phase 3 randomized controlled trial, a late-stage milestone that could support regulatory submission if successful [sec].
- The company raised $100M in equity financing in 2025-2026, indicating investor support and providing near-term capital runway [sec_mda · as of 2026-08-06].
- Lyell has internal manufacturing capabilities, which may reduce reliance on external contract manufacturers and improve control over production [sec_mda · as of 2026-08-06].
What to weigh
- Lyell has no approved products and no revenue, with a net loss of $44.8M in the most recent quarter, reflecting high R&D spending [sec].
- The company will need additional capital beyond the next 12 months to fund further development and commercialization, creating financing risk [sec_mda · as of 2026-05-06].
- Clinical-stage biotech companies face inherent risks of trial failures, adverse events, and regulatory delays that could materially affect the business [sec · filed 2025-06-17].
From the filings
Quoted directly from source documents.
Company expects to need additional capital
“we anticipate that we will need to raise additional capital in the future to fund our operations, including further development of our product candidates and the commercialization of any approved product candidates.”
SEC MD&A · May 6, 2026
Company raised $50M in March 2026
“On March 6, 2026, we issued 1,952,360 shares of common stock at a purchase price of $25.61 per share at a subsequent closing pursuant to the SPA for gross proceeds of approximately $50.0 million.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2032-01-01 · Phase3_Topline · rondecabtagene — Phase 3 Topline — Topline results from the Phase 3 randomized controlled trial of rondecabtagene autoleucel will be a key efficacy and safety readout for the lead candidate.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Lyell has no commercial products and generated $0 revenue as of 2026-06-30, relying on external financing [sec].
- Need for future capital — Cash runway is limited to ~12 months; additional capital will be required for development and commercialization [sec_mda · as of 2026-05-06].
- Clinical trial risks — Phase 3 trial may fail to meet endpoints, or safety issues may arise, delaying or preventing approval [sec · filed 2025-06-17].
- Regulatory and manufacturing delays — Costs and timing of regulatory review and manufacturing scale-up could adversely affect timelines [sec_mda · as of 2026-08-06].
What to watch
- Phase 3 topline data for rondecabtagene autoleucel, expected by 2032-01-01 [sec].
- Cash runway updates and any future financing activities, as current cash is expected to last ~12 months from 2026-05-06 [sec_mda · as of 2026-05-06].
- Regulatory interactions and any updates on manufacturing scale-up for the lead candidate [sec_mda · as of 2026-08-06].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Lyell Immunopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lyell Immunopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
17.8 months
D/E 0.33 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
1 upcoming, next in ~1950d
2 buys · 11 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$185.5M
| Holder | Shares | Value |
|---|---|---|
| arch venture management, llc | 3,247,162 | $65.1M |
| vanguard capital management llc | 1,436,310 | $28.8M |
| orland properties ltd | 754,698 | $15.1M |
| millennium management llc | 458,905 | $9.2M |
| citadel advisors llc | 393,462 | $7.9M |
| venbio partners llc | 337,697 | $6.8M |
| susquehanna international group, llp | 310,198 | $6.2M |
| alphabet inc. | 293,256 | $5.9M |
| blackrock, inc. | 191,820 | $3.8M |
| geode capital management, llc | 166,980 | $3.4M |
Showing top 10 of 71 institutional holders of Lyell Immunopharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 6.8%
- Days to cover
- 15.4
- Shares short
- 1,344,189
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LYEL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lyell Immunopharma, Inc.?
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company developing cell therapies for cancer, with a lead dual-targeting CAR T-cell candidate in Phase 3 trials and a cash position of $74.6M as of 2026-06-30.
What is Lyell Immunopharma, Inc.'s lead drug candidate?
Lyell Immunopharma, Inc.'s most advanced tracked candidate is impt-314 (Phase 2) for Relapsed/refractory aggressive large B-cell lymphoma.
What is Lyell Immunopharma, Inc.'s next catalyst?
Lyell Immunopharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting C" — expected January 1, 2032.
Who is the CEO of Lyell Immunopharma, Inc.?
Dr. Lynn Seely M.D., Ph.D. is the chief executive officer of Lyell Immunopharma, Inc. (LYEL).
Where is Lyell Immunopharma, Inc. headquartered?
Lyell Immunopharma, Inc. (LYEL) is headquartered in South San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.